Indian contract research and manufacturing firms have increased capital spending by 93% between FY21 and FY26 to target high-value drug markets. While this expansion aims to capture global demand for complex products, investors should monitor execution risks and the time needed for these facilities to become profitable.
Indian contract research, development, and manufacturing (CRDMO) companies are undergoing a major transition. According to industry data, capital expenditure across nine major firms in the sector increased by nearly 93% between fiscal years 2021 and 2026. This aggressive spending reflects a strategic pivot from basic manufacturing to high-value, complex segments.
Companies such as Divi’s Laboratories, Laurus Labs, Piramal Pharma, Blue Jet Healthcare, and Sai Life Sciences are heavily investing in specialized technologies. This includes the development of antibody-drug conjugates, peptides, oligonucleotides, and high-potent active pharmaceutical ingredients. These products are significantly more difficult to engineer than traditional generic drugs, creating a potential business advantage for Indian firms that can successfully master these technologies.
Moving toward these specialized areas is designed to make Indian companies essential partners for global pharmaceutical giants. Instead of competing solely on price in the generic market, these firms aim to become integrated partners in the research and development phase of new drugs. This strategy is driven by a desire to capture a larger share of the global pharmaceutical supply chain as international clients look to diversify their manufacturing bases.
While this expansion signals growth, it brings important considerations for investors. These specialized facilities require significant upfront investment, which can lead to higher depreciation and interest costs in the short term. Because these complex modalities—such as biologics—have longer development and validation periods, it often takes several years before new capacity starts contributing significantly to profit margins.
There is also an execution risk. If the demand for these specific new drugs does not materialize as expected, or if global pharmaceutical clients change their outsourcing strategies, the high capital spending could put pressure on the balance sheets of these companies. Additionally, firms in this sector remain sensitive to regulatory outcomes. Any delays in facility approvals or audit issues from agencies like the US FDA can directly impact the timeline for when these new investments become productive.
Investors may monitor how quickly these companies can fill their new capacity with high-margin orders. Key indicators will be the utilization rates of these new plants, management commentary on order book growth, and the ability to maintain profit margins despite the higher costs associated with scaling these complex technologies.